maximum weight loss tirzepatide surmount trials SURMOUNT-3 study design This is a phase 3, multicenter, randomized, SURMOUNT-MAINTAIN: Drop Your Tirzepatide Dose?

(I wrote about Medicare approval and these drugs in detail previously.) The impediment to the weight loss industrys ultimate goal of Medicare coverage is that after the Fen-Phen disaster harmed and killed higher-weight people, Medicare stopped covering weight loss drugs

Participants who continued treatment maintained and extended their losses, reaching 25.3% total weight reduction from baseline at 88 weeks

Limit very high-protein meals Eating a lot of meat, eggs, or protein shakes can make urine smell stronger or more ammonia-like

P = 0.03)

The policy was supposed to have come into effect on Jan.1, but opposition from a broad base of GA groups prompted a deferral until March 1

Orforglipron: The First Approved Oral Non-Peptide GLP-1R Agonist for Obesity | drughunters.com/4tP9Jut Orforglipron is now FDA approved for obesity, marking a major milestone for orally available small molecule GLP-1 therapies